Skip to main content
Figure 3 | Genetic Vaccines and Therapy

Figure 3

From: Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours

Figure 3

Subcutaneous and metastatic LLC growth following AAV-mediated Nk4 Gene Therapy. (a) AAVNk4 expression in vitroLLC cells were transduced with AAVNk4 particles in vitro. cDNA was prepared from total RNA extracted at 48 h, and subjected to Nk4 specific RT-PCR as before. Lane 1 = RNA from LLC transduced with AAVNk4 particles, lane 2 = RNA from untransduced LLC cells, lane 3 = H2O template control. (b) AAV transduction of LLC tumours In vivo luminescence in LLC tumour following i.t. adminstration of AAV-CMV Luc particles. Image from IVIS Imaging System showing luciferase expression on day 9 post i.t. injection of AAV-Luc particles (2.91 × 10-3 p/sec/cm2/sr/particle). (c) In vivo treatment of growing LLC tumours with AAV-Nk4Established LLC tumours were i.t. administered AAV-Nk4 or AAV-BB (control) or no particles (PBS) and growth monitored (n = 6). Tumour growth in the AAV-Nk4 group was significantly reduced (*p < 0.05) when compared with the AAV-BB injected control group, and while the untreated group growth was also higher than the Nk4 group, it proved to be statistically insignificant. (d) Number of lung metastases following AAV-Nk4 therapyVisual analysis and comparison of surface metastatic nodules at days 21 and 26 showed that the Nk4 treated group had fewer nodules compared with the BB and untreated control group. A statistically significant difference could be seen between the combined day 21 and day 26 data from the Nk4 treated group and the BB control group (p = 0.015) (n = 3/group/timepoint). (e) Volume of lung metastases following AAV-Nk4 therapyMetastatic nodules were measured at days 21 and 26 and the average volume calculated. Both control groups had a larger metastatic burden than the Nk4 treated group with a significant difference between the Nk4 and untreated group (p = 0.021) and the BB group (p = 0.012).

Back to article page